MXCT
HEALTHCAREMaxCyte Inc
Live · NASDAQ · May 9, Close
What's Moving MXCT Today?
No stock-specific AI insight has been generated for MXCT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.85
Fundamentals
Trading
MXCT News
20 articles- MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026Yahoo Finance·Apr 29, 2026
- MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Mar 31, 2026
- MaxCyte, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 25, 2026
- MaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ...Yahoo Finance·Mar 25, 2026
- MaxCyte (MXCT) Q4 2025 Earnings Call TranscriptMotley Fool·Mar 24, 2026
- MaxCyte Q4 Earnings Call HighlightsMarketbeat·Mar 24, 2026
- MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 24, 2026
- MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 GuidanceYahoo Finance·Mar 24, 2026
- MaxCyte Appoints Parmeet Ahuja as Chief Financial OfficerYahoo Finance·Mar 23, 2026
- MaxCyte (MXCT) Launches ExPERT DTx Platform to Accelerate High-Throughput Drug DiscoveryYahoo Finance·Feb 25, 2026
- MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discoveryYahoo Finance·Feb 24, 2026
- MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026Yahoo Finance·Feb 23, 2026
- MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Jan 12, 2026
- Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPOYahoo Finance·Dec 1, 2025
- MaxCyte Inc (MXCT) Q3 2025 Earnings Call Highlights: Strategic Moves Amidst Market ChallengesYahoo Finance·Nov 13, 2025
- MaxCyte Announces Planned CFO Transition in 2026Yahoo Finance·Nov 12, 2025
- MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue GuidanceYahoo Finance·Nov 12, 2025
- Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue EstimatesYahoo Finance·Nov 10, 2025
- ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat EstimatesYahoo Finance·Nov 7, 2025
- MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue GuidanceYahoo Finance·Nov 5, 2025
All 20 articles loaded
Price Data
52-Week Range
$0.85
Fundamentals
Trading
About MaxCyte Inc
MaxCyte Inc. (MXCT) is a pioneering company in the field of cell-engineering, distinguished by its innovative Flow Electroporation® technology, which facilitates the efficient and scalable introduction of nucleic acids and proteins into various cell types. Serving a diverse clientele that includes leading biopharmaceutical companies and prominent research institutions, MaxCyte is strategically positioned in the burgeoning cell and gene therapy market. The company's cutting-edge platforms are integral to the development of novel cell-based therapies and vaccines, allowing it to seize substantial growth opportunities within the healthcare landscape. Committed to advancing transformative medical solutions, MaxCyte is set to meet the increasing global demand for innovative therapeutic approaches.